Short and Optimal Duration of Dual Antiplatelet Therapy Study
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1525 participants.
Also called NCT01659034
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,525 participants
- Sponsor
- Registry
-
NCT01659034
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT01659034. Allocation not applicable; no masking; primary purpose treatment. Start 2012-09 (registry gives no type); primary completion 2014-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Short and Optimal Duration of Dual Antiplatelet Therapy Study
- Acronym
- STOPDAPT
- Condition
- Coronary Artery Disease
- Intervention (Drug)
- Thienopyridine for 3 months
- Lead sponsor
- Takeshi Morimoto
Record details
- Record id
cardio:ct-nct01659034- Content hash
5a58c69f65d949bab68eb9b8c973584ac519e3ef6e749f9d6174ee00aab09f5b